Efficacy of transfer factor in treating patients with recurrent ocular herpes infections.

Abstract

Recurrent ocular herpes is an insoluble problem for the clinician. As cellular immunity plays an important role in controlling herpes relapses, and other studies have shown the efficacy of HSV-specific transfer factor (TF) for the treatment of herpes patients, an open clinical trial was undertaken in 134 patients (71 keratitis, 29 kerato-uveitis, 34 uveitis) suffering from recurrent ocular herpetic infections. The mean duration of the treatment was 358 days, and the entire follow-up period 189,121 before, and 64,062 days after TF treatment. The cell-mediated immune response to the viral antigens, evaluated by the lymphocyte stimulation test (LST) and the leucocyte migration test (LMT) (P < 0.001), was significantly increased by the TF treatment. The total number of relapses was decreased significantly during/after TF treatment, dropping from 832 before, to 89 after treatment, whereas the cumulative relapse index (RI) dropped, during the same period, from 13.2 to 4.17 (P < 0.0001). No side effects were observed. It is concluded that patients with relapsing ocular herpes can benefit from treatment with HSV-specific TF.

• Authors: R Meduri, E Campos, L Scorolli, C De Vinci, G Pizza, D Viza
• Journal: Biotherapy (Dordrecht, Netherlands) (Biotherapy) Vol. 9 Issue 1-3 Pg. 61-6 ( 1996) ISSN: 0921-299X [Print] Netherlands
• PMID: 8993759 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antibodies, Viral
• Antiviral Agents
• Transfer Factor

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Animals
• Antibodies, Viral (blood)
• Antiviral Agents (immunology, therapeutic use)
• Cattle
• Child
• Child, Preschool
• Female
• Humans
• Immunity, Cellular (drug effects, immunology)
• Keratitis, Herpetic (immunology, therapy)
• Male
• Middle Aged
• Sensitivity and Specificity
• Simplexvirus (immunology)
• Transfer Factor (immunology, therapeutic use)
• Uveitis (immunology, therapy)